ReviewProceedings of the Japan Academy. Series B, Physical and biological sciences2012
Vascular permeability in cancer and infection as related to macromolecular drug delivery, with emphasis on the EPR effect for tumor-selective drug targeting.
Review in Proceedings of the Japan Academy. Series B, Physical and biological sciences, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 92 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
92 citing papers in PubMed.
- Trial
- A Synergistic Approach Using a ROS-Responsive Lipid-Based Prodrug for Liposomal Delivery of Doxorubicin.Bioconjugate chemistry · 2026Article
- Tumor-Selective Vascular Modulation by Acid-Cleavable Retro-Inverso Bradykinin Conjugates Enhances the Antitumor Efficacy of Nanomedicine.ACS omega · 2026Article
- A microscopic computational simulation of [Physics in medicine and biology · 2026Article
- Therapeutic potential of allicin against viral infections: Mechanisms and safety profile (Review).Experimental and therapeutic medicine · 2026Review
- Poor prognosis outcome tumors, bacteria-infected tumors and nanodrugs: current evidence and hypotheses towards a paradigm change for treatment.Cancer biology & medicine · 2026Review
- Endothelial dysfunction determines vascular mechanisms of metastatic progression in breast cancer.Discover oncology · 2026Review
- Targeting of Bacteria Using Amylase-Degradable, Copper-Loaded Starch Nanoparticles.Antibiotics (Basel, Switzerland) · 2026Article
- Latest advances in nanodrug delivery systems for modulating the immune microenvironment in triple-negative breast cancer.Frontiers in immunology · 2026Review
- Comparative Analysis of Physical and Polymer Characteristics of Microplastics Detected in Human Colorectal Cancer Samples From the United States and Malaysia.Journal of gastroenterology and hepatology · 2025Article
- Nanocarrier-Based Systems for Targeted Delivery: Current Challenges and Future Directions.MedComm · 2025Review
- Directed discovery of high-loading nanoaggregates enabled by drug-matched oligo-peptide excipients.Chem · 2025Article
- Emerging nanoparticle-based x-ray imaging contrast agents for breast cancer screening.Nanomedicine (London, England) · 2025Review
- Targeted nanoparticles for imaging and therapy of endometriosis†.Biology of reproduction · 2024Review
- Nanotechnology for the Diagnosis and Treatment of Liver Cancer.International journal of nanomedicine · 2024Review
- Targeted nanodelivery systems for personalized cancer therapy.Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology · 2024Review
- Enhancing the Treatment of Uncontrolled Inflammation through the Targeted Delivery of TPCA-1-Loaded Nanoparticles.Pharmaceutics · 2023Article
- Dopamine-Conjugated Bovine Serum Albumin Nanoparticles Containing pH-Responsive Catechol-V(III) Coordination for In Vitro and In Vivo Drug Delivery.Biomacromolecules · 2023Article
- New Pathway for Cisplatin Prodrug to Utilize Metabolic Substrate Preference to Overcome Cancer Intrinsic Resistance.ACS central science · 2023Article
- Recent development of surface-enhanced Raman scattering for biosensing.Journal of nanobiotechnology · 2023Review
32 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tumor and inflammation have many common features. One hallmark of both is enhanced vascular permeability, which is mediated by various factors including bradykinin, nitric oxide (NO), peroxynitrite, prostaglandins etc. A unique characteristic of tumors, however, is defective vascular anatomy. The enhanced vascular permeability in tumors is also distinctive in that extravasated macromolecules are not readily cleared. We utilized the enhanced permeability and retention (EPR) effect of tumors for tumor selective delivery of macromolecular drugs. Consequently, such drugs, nanoparticles or lipid particles, when injected intravenously, selectively accumulate in tumor tissues and remain there for long periods. The EPR effect of tumor tissue is frequently inhomogeneous and the heterogeneity of the EPR effect may reduce the tumor delivery of macromolecular drugs. Therefore, we developed methods to augment the EPR effect without inducing adverse effects for instance raising the systemic blood pressure by infusing angiotensin II during arterial injection of SMANCS/Lipiodol. This method was validated in clinical setting. Further, benefits of utilization of NO-releasing agent such as nitroglycerin or angiotensin-converting enzyme (ACE) inhibitors were demonstrated. The EPR effect is thus now widely accepted as the most basic mechanism for tumor-selective targeting of macromolecular drugs, or so-called nanomedicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.